Chiesi’s Raxone recommended for use within NHS Wales
Medicine recommended for the treatment of visual impairment in Leber’s Hereditary Optic Neuropathy
Read Moreby Lucy Parsons | Apr 27, 2021 | News | 0
Medicine recommended for the treatment of visual impairment in Leber’s Hereditary Optic Neuropathy
Read Moreby Selina McKee | Jun 22, 2018 | News | 0
UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAMS) for another year.
Read Moreby Selina McKee | Mar 6, 2018 | News | 0
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.
Read Moreby Selina McKee | Jan 29, 2018 | News | 0
Santhera’s attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.
Read Moreby Selina McKee | Jun 22, 2017 | News | 0
Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).
Read Moreby Selina McKee | May 9, 2017 | News | 0
The Scottish Medicines Consortium has endorsed three medicines for routine use by NHS Scotland, offering new options to treat a rare eye disease, lupus and infertility.
Read Moreby Selina McKee | Jun 22, 2016 | News | 0
European regulators have validated Santhera’s marketing application for Raxone as a treatment for certain patients with Duchenne muscular dystrophy.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
